Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.

Stem Cell Res Ther · 2022 · PMC9241239 · PMID 35765103

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Also, in the control group, a decreasing trend in the level of this cytokine was observed during the study period.

also in 47,180 other papers

an increasing trendno p-value reported

On the 17th day, an increasing trend was observed in the levels of this cytokine which this increase was statistically insignificant in the control group (24.24 ± 7.34) but was significant in the intervention group (42.52 ± 9.11, P = 0.005).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.